How APAC life sciences companies can master FDA 21 CFR Part 11 compliance

From biotech startups in Melbourne and medical device innovators in Tokyo to contract research organisations (CROs) in Singapore, APAC companies are eyeing the world’s largest healthcare playground: the US. Many are already there, with an increasing proportion of Food and Drug Administration (FDA) approvals originating from non-US-headquartered sponsors across Japan, South Korea, Australia, India, and China.

But for others, navigating the path to US market entry is hard. Your science may be world-class, but if your electronic records and signatures don’t meet US regulatory standards, your market access is at risk before your product ever reaches a patient.

It’s why every company targeting the US needs to adhere to the gold standard of data integrity: the FDA’s 21 CFR Part 11.

What is the 21 CFR Part 11?

No matter how familiar your team is with local frameworks like Australia’s Therapeutic Goods Association (TGA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), or Singapore’s Health Sciences Authority (HSA), the US Code of Federal Regulations (CFR) adds a whole new layer of complexity.

There’s a great primer on 21 CFR Part 11 here. But the golden rule for non-US companies is this: it doesn’t matter where your headquarters are. If your electronic records or signatures are part of a submission to the FDA, then they must comply with Part 11. Which means they must include these core pillars:

• The printed name of the signer

• The date and time the signature was executed

• A unique user ID

• Digital adopted signature 

• The meaning of the signature (labeled “signing reason”)

The thing is, local frameworks like the TGA often lack the highly specific rules that the FDA enforces.

Why is compliance so hard?

Across APAC, it’s common for healthcare companies to run into trouble when trying to comply with 21 CFR Part 11. For starters, many still use physical signatures or stamps – the Japanese hanko, for example, is a rich part of business culture.  

There’s also often fragmentation across jurisdictions. For example, a company might base its R&D in Australia, with clinical trials in South Korea, and a manufacturing hub in Singapore. If they each use their own siloed document management systems, massive gaps appear in audit trails.

And then there’s the challenge of balancing local data sovereignty laws with the FDA’s accessibility requirements. Finding a platform that satisfies both sides of the equation can be tricky. 

How does Docusign IAM solve the compliance conundrum?

Docusign eSignature supports 21 CFR Part 11 straight out of the box. With pre-configured signature manifestation fields, robust multi-factor signer authentication, and tamper-evident completion seals, it’s got the FDA tick of approval for validating documents. 

With Docusign, it’s easy to deploy a single signing platform across all your global sites. So whether a document is generated in Melbourne, Tokyo or Hyderabad, it meets the same FDA-grade standard. What’s more, it complies with local electronic signing laws, too. 

Behind the scenes, Docusign IAM’s robust capabilities help streamline the process of managing the complex contracts and agreements that drive healthcare research. And AI-powered reviews help spot non-standard clauses or anything that might raise a regulatory red flag.  

What does it look like in action?

Let’s use a fictional Melbourne-based biotech as an example. They’re busy preparing an Investigational New Drug (IND) submission to the FDA, pitching Australia’s attractive R&D tax incentives. Their electronic lab notebooks and quality protocols require Part 11-compliant signatures – which, with Docusign IAM in play, is no problem. Validated e-signatures are captured across their R&D and quality teams, creating a single, digital audit trail that satisfies both the FDA and the TGA.

Or what about a Japanese medtech company that wants to export to the US? Because FDA inspectors can request access to quality system records (such as CAPA and design controls) at any time, the company manages these files via Docusign CLM. When an audit occurs, they can instantly pull up complete, tamper-evident records, regardless of whether the original signer was located in Osaka or Ohio.

As these examples show, a globally consistent platform like Docusign helps transform compliance from a stressful barrier into a streamlined competitive advantage.

Turn compliance into a competitive advantage

While adherence to 21 CFR Part 11 might feel hard or overwhelming, it’s actually great business practice. If you can confidently show that your workflows are validated, verifiable, auditable, and secure, then you’re showing not just US investors but the whole world that you operate at the highest global standards. 

To learn more about how Docusign helps ensure your regulatory processes hold firm whether you’re signing in Sydney, Singapore, or San Francisco, get in touch for a more detailed chat about this complex topic.